Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
N/A
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07041203Phase 1Not Yet Recruiting

Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor

Role: lead

NCT03292458Phase 2Completed

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

Role: lead

NCT03042975Recruiting

Imaging Genetics of Laryngeal Dystonia

Role: lead

NCT04421365Not ApplicableRecruiting

Brain-Computer Interfaces in Laryngeal Dystonia

Role: lead

NCT01961297Phase 2Completed

Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response

Role: lead

All 5 trials loaded